



## 저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학석사 학위논문

**Association between Serum  
1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and Carotid  
Plaques and Intima-Media  
Thickness**

**혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도와  
경동맥 경화반 및 내중막 두께와의  
연관성**

2013년 2월

서울대학교 대학원  
의학과 가정의학 전공  
김 계 형

↑ 2cm ↓	혈중 1,25(OH) <sub>2</sub> vitamin D3 농도와 경동맥 경화반 및 내장막 두께와의 연관성	
↑ 2.5cm ↓	2012년	
↑ 4cm ↓		
↑ 3cm ↓	김계형	
↑ 2cm ↓		

Association between Serum 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> and Carotid Plaques and Intima-Media Thickness	2012
Kyrae Hyung Kim	
↑ 2cm ↓	↑ 2.5cm ↓
	↑ 4cm ↓
	↑ 3cm ↓
	↑ 2cm ↓

# Association between Serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and Carotid Plaques and Intima- Media Thickness

지도 교수 조 비 룡

이 논문을 의학석사 학위논문으로 제출함  
2012년 10월

서울대학교 대학원  
의학과 가정의학 전공  
김 계 형

김계형의 의학석사 학위논문을 인준함  
2012년 12월

위 원 장	<u>이 경 구</u>	(인)
부위원장	<u>조 비 룡</u>	(인)
위 원	<u>신 흥 욱</u>	(인)

# **Association between Serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and Carotid Plaques and Intima- Media Thickness**

by  
**Kyae Hyung Kim**

**A thesis submitted to the Department of Family Medicine in partial  
fulfillment of the requirements for the Degree of Master of Science in  
Family Medicine at Seoul National University College of Medicine**

**December 2012**

**Approved by Thesis Committee:**

Professor	<u>Yong Joo Park</u>	Chairman
Professor	<u>Beom Cho</u>	Vice chairman
Professor	<u>Dong Wook Shin</u>	

## 학위논문 원문제공 서비스에 대한 동의서

본인의 학위논문에 대하여 서울대학교가 아래와 같이 학위논문 제공하는 것에 동의합니다.

### 1. 동의사항

- ① 본인의 논문을 보존이나 인터넷 등을 통한 온라인 서비스 목적으로 복제할 경우 저작물의 내용을 변경하지 않는 범위 내에서의 복제를 허용합니다.
- ② 본인의 논문을 디지털화하여 인터넷 등 정보통신망을 통한 논문의 일부 또는 전부의 복제, 배포 및 전송 시 무료로 제공하는 것에 동의합니다.

### 2. 개인(저작자)의 의무

본 논문의 저작권을 타인에게 양도하거나 또는 출판을 허락하는 등 동의 내용을 변경하고자 할 때는 소속대학(원)에 공개의 유보 또는 해지를 즉시 통보하겠습니다.

### 3. 서울대학교의 의무

- ① 서울대학교는 본 논문을 외부에 제공할 경우 저작권 보호장치(DRM)를 사용하여야 합니다.
- ② 서울대학교는 본 논문에 대한 공개의 유보나 해지 신청 시 즉시 처리해야 합니다.

논문제목 : Association between Serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and Carotid Plaques and Intima-Media Thickness


학위구분 : 석사 ■ · 박사 □

학 과 : 가정의학교실

학 번 : 2010-21779

연 락 처 :

저 작 자 : 김 계 형 (인)



제 출 일 : 2013 년 2 월 4 일

서울대학교총장 귀하

## Agreement of Thesis Disclosure

(Do not include this English form in the thesis copy. Use the Korean form in the previous page.)

I approve the thesis distribution service offered by Seoul National University under the following agreement.

### 1. Agreement

- ① I approve the duplication of the thesis for the purpose of archiving or online service via internet as long as the contents of the thesis are not modified.
- ② I approve free duplication, distribution, and transmission of the entire (or partial) thesis in digital format via internet or similar network.

### 2. Author Responsibility

When the copyright of the thesis is transferred to others or is allowed to be published for any reason that may invalidate this agreement, I will immediately notify the College to defer or stop distributing the copyrighted contents.

### 3. University Responsibility

- ① The University must protect the copyright of the thesis under digital rights management (DRM) when providing the thesis to outside individuals or parties.
- ② The University must process the request for the deferment or suspension of the thesis distribution immediately.

Thesis Title : Association between Serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and Carotid Plaques and Intima-Media Thickness


Degree : **Master's** ■ **Ph.D.** □

Department: Department of Family Medicine

Student number: 2010-21779

Contact info:

Author name: Kyae Hyung Kim (stamp)



Submission date : 2013 년 2 월 4 일

**Attn: President of Seoul National University**



## 초 록

**서론:** 많은 연구결과들에 의하여 낮은 농도의 비타민 D가 심혈관 질환과 연관되어 있다고 알려져 있으나 심혈관계 질환 예방을 위한 최적의 비타민 D 농도는 아직 밝혀져 있지 않다. 이에 본 연구는 한국 성인에서 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도와, 불현성 동맥경화 지표인 경동맥 경화반 및 내중막 두께와의 연관성을 알아보고자 하였다.

**방법:** 본 연구는 2006년 3월 1일부터 2009년 12월 30일까지 서울대학교 병원 건강증진센터를 내원한 19-85세 사이의 1,815 명의 한국 성인남녀를 대상으로 하였다. 경동맥 초음파를 이용하여 경동맥 내중막 두께, 경동맥 경화반의 유무, 개수, 부피를 측정하여 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 5분위수 농도와 상관관계를 분석하였다.

**결과:** 여성 참가자들에서 경동맥 경화반의 유무, 개수, 부피는 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도와 J 또는 U 커브의 상관관계를 보였다. 다변량 로지스틱 회귀분석 모형에서 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도의 제 3분위수 (31.8-38.8 pg/ml) 와 제 4분위수 (31.8-38.8 pg/ml) 농도에서 경동맥 경화반이 유의하게 감소하였으며, 그 오즈비는

각각 0.26 (95% confidence interval [CI], 0.09–0.74) , 0.38 (95% CI, 0.15–0.94) 이었다. 경동맥 경화반의 개수와 부피를 Analysis of covariance로 분석하였을 때도 제 3분위수와 4분위수의 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도에서 유의하게 감소하는 결과를 보였다. 남성 참가자들에서는 경동맥 경화반과 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도의 유의한 관계를 관찰할 수 없었다. 또한 모든 참가자들에게서 경동맥 내중막 두께와 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도의 관계는 통계적으로 유의하지 않았다.

**결론:** 본 연구결과로 미루어 볼 때 한국 여성에게서 매우 낮거나 높은 농도가 아닌 적절한 혈중 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> 농도에서 경동맥 경화반의 감소가 관찰되었다. 이와 관련하여 향후 심혈관계 질환 예방을 위한 최적의 비타민 D 농도를 탐구하는 다양한 전향적인 연구가 필요할 것으로 생각된다.

---

**주요어:** 경동맥 경화반, 경동맥 내중막 두께, 경동맥 경화, 비타민 D, 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub>

**학 번:** 2010-21779

# Abstract

## Introduction

Many epidemiological studies have found that low vitamin D level is associated with cardiovascular diseases. But the optimal level for cardiovascular health remains unclear. The present study aimed to assess the association between 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and subclinical carotid atherosclerosis.

## Methods

1,815 Korean participants aged 19-86 who underwent medical checkups were enrolled between March 2006 and December 2009. Cross-sectional relationships between quintiles of serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and common carotid artery (CCA) structures using ultrasonography (CCA intima-media thickness [IMT], occurrence, numbers, and volume of plaque) were investigated adjusting for possible confounders.

## Results

Among female participants, occurrence of plaque, numbers and volumes of CCA plaques showed the J or U shaped association with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration. In the concentration of 3rd quintile (31.8-38.8 pg/ml) and 4th quintile (38.9-48.5 pg/ml), participants showed decreased adjusted Odds

ratio (aOR) for occurrence of CCA plaque (aOR 0.26, 95% confidence interval [CI], 0.09–0.74, 3<sup>rd</sup> quintile and aOR 0.38, 95% CI, 0.15–0.94, 4<sup>th</sup> quintile, respectively) in multivariate logistic regression model. Similarly, decreased number and volume of CCA plaque were demonstrated in of 3<sup>rd</sup> and 4<sup>th</sup> quintile ( $p=0.022$  and  $0.023$  for number of plaque, and  $p=0.030$  and  $0.020$  for volume of plaque in analysis of covariance [ANCOVA], respectively). Among male participants, we found no association between occurrence, numbers and volumes of CCA plaques and  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration. We found no significant association between CCA IMT and  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration both in ANCOVA and in multivariate logistic regression analysis in the whole participants.

## Conclusions

The results of present study indicate that adequate vitamin D concentration, not too low or too high level, is associated with decrease of subclinical carotid atherosclerosis among Korean women, but not among Korean men. Further studies are needed to elucidate optimal levels of vitamin D for cardiovascular health.

---

**Keywords:** carotid intima-media thickness, carotid plaque, carotid atherosclerosis, vitamin D,  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$

**Student Number:** 2010-21779

# Contents

<b>Introduction</b>	1
<b>Materials and Methods</b>	4
<i>Study population</i>	4
<i>Question survey, anthropometric and laboratory assessments</i>	6
<i>Serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> measurement</i>	7
<i>Measurement of carotid artery structure</i>	10
<i>Statistical analysis</i>	10
<b>Results</b>	14
<i>Baseline characteristics</i>	14
<i>Univariate Correlations of various cardiovascular risk factors and mean</i>	
<i>CCA-IMT</i>	20
<i>The associations between 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and Carotid</i>	
<i>atherosclerosis indexes</i>	22
<b>Discussion</b>	28
<b>Conclusion</b>	33
<b>Reference</b>	34

# Lists of Table and Figures

<b>Table 1.</b> Characteristics of study participants according to 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> concentration in men -----	16
<b>Table 2.</b> Characteristics of study participants according to 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> concentration in women -----	18
<b>Table 3.</b> Pearson' s correlation coefficients for univariate associations between various risk factors and mean CCA IMT-----	21
<b>Table 4.</b> Mean values of carotid indexes of participants according to of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> concentration in men-----	24
<b>Table 5.</b> Mean values of carotid indexes of participants according to of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> concentration in women-----	25
<b>Table 6.</b> Association of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> concentration and increased carotid atherosclerosis in men -----	26
<b>Table 7.</b> Association of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> concentration and increased carotid atherosclerosis in women -----	27
<b>Figure 1.</b> Flow diagram of inclusion or exclusion of study participants-----	5
<b>Figure 2.</b> Seasonal distribution of 1,25 (OH) <sub>2</sub> vitamin D <sub>3</sub> concentration of study participants-----	9
<b>Figure 3.</b> Histogram of 1,25 (OH) <sub>2</sub> vitamin D <sub>3</sub> concentration of study participants-----	12
<b>Figure 4.</b> Distribution of mean CCA IMT of study participants-----	13

## Introduction

Vitamin D inadequacy is highly prevalent across the world. In United States, the proportions with serum 25(OH)D levels below 30 ng/mL were 73%, 89%, and 95% in the females in age categories of 1–5, 20–49, and 70 years and older. (1) In Asian countries, prevalence rate among postmenopausal women using this cut-off value of 30ng/mL of serum 25(OH)D levels is 92% in Korea, 90% in Japan, and 47% in Thailand respectively (2).

Many epidemiological and biological studies have found that low level of vitamin D is associated with non-skeletal conditions such as obesity (3) hypertension (4) diabetes (5, 6) cardiovascular (7) or cerebrovascular outcomes (8) and mortality (9). The mechanism is not fully elucidated. Vitamin D, the major steroid hormone absorbed from the skin and diet, is metabolized in the liver to 25 (OH) vitamin D (10, 11). Then, 25 (OH) vitamin D, the major circulating and storage form of vitamin D, is metabolized in the kidneys by the enzyme 1-alpha-hydroxylase to its active form, 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> (10, 11). Some studies demonstrated that vitamin D receptors and 1-alpha-hydroxylase are known to be present in vascular endothelial cells (12) and known to display anti-hypertrophic activity in the animal heart (13). Vitamin D also upregulates glucose transporter 4 (GLUT4) translocation and glucose utilization (14), decreases lipogenesis (15), as well as induces anti-atherogenic monocyte/macrophage phenotype (16).

Undoubtedly, vitamin D deficiency is the most common nutrition-responsive medical condition (17). Therefore, it would be an effective strategy to identify

the risk of vitamin D inadequacy in preclinical stage and correct its level to adequacy to prevent further diseases. Guidelines define adequate 25(OH) vitamin D<sub>3</sub> concentration as greater than 30ng/mL (10, 18). And they also define vitamin D insufficiency exists at concentrations between 15 and 30 ng/mL, and deficiency at concentrations less than 15 ng/mL (10, 18). But there is no higher cut-off value of it adequacy. Recently, several studies suggested that both low and high levels of vitamin D linked to increased mortality (19, 20), but there is a lack of evidence for morbid cardiovascular diseases. Moreover, not only in cardiovascular mortality or morbidity, but there is also a need for more evidences in primordial conditions in the general population. Bogalusa Heart study and Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study revealed that young person, even a youth of twenties, could already have subclinical atherosclerosis and the prevention of cardiovascular disease should begin early in life (21, 22). In this context, there is a special need for studies that also evaluate the association of subclinical atherosclerosis and optimal vitamin D concentration.

Sabanayagam et al found vitamin D deficiency is associated with prehypertension in a representative sample of US adults (23). Gonzalez-Molero and Huwemoen respectively reported that subjects with vitamin D deficiency showed high incidence of diabetes in a prospective study (24, 25). Kojima et al found Low dietary vitamin D predicts 34-year incident stroke (8). Those studies focused on low levels of vitamin D with subclinical vascular conditions. However, higher level of vitamin D, below toxicity level, has not



been an object of concern.


Carotid Intima-media thickness (IMT) is a surrogate marker for subclinical atherosclerosis and predicts future cardiovascular and cerebrovascular outcomes (26). High-resolution B-mode Ultrasonography is known to detect changes in the arterial wall structure, including intima-media thickness (IMT), atherosclerotic plaque, and plaque volume (27). Recently, carotid plaque are also known to be an important predictor of cardiovascular disease events as well (28, 29). We evaluated both CCA IMT and plaque. In regards to assess vitamin D status, we used 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration in the present study. Although 25-OH vitamin D is recommended to determine a patient' s vitamin D status (10), however, previous studies showed that both 25 (OH) vitamin D<sub>3</sub> and 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> levels may show independent associations for cardiovascular outcomes (30). In the present study, our aim was to study in a cross-sectional analysis whether serum serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration are associated with carotid IMT, number of plaque, or plaque volumes among 962 men and 853 women in Korea.

## **Materials and Methods**

### ***Study population***

The participants in this study were screened as detailed in Figure 1. Among the persons who visited the Health Promotion Center, Seoul National University Hospital, for health check-ups from March 1st 2006 to December 30th 2009, only those who underwent Cardiovascular Health Examination Package including serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> were selected. Participants who had undergone anthropometric measurements, health questionnaire survey and laboratory tests including measurement of serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub>, and carotid ultrasonography were included in the study. The health questionnaire survey was double-checked through health interviews by health screening doctors. In total, 1,815 participants were included in the study. All the participants provided informed consent. The study procedures followed the tenets of the Declaration of Helsinki and were approved by the Institutional Review Board of Seoul National University Hospital.

**Figure 1.** Flow diagram of inclusion or exclusion of study participants



## ***Question survey, anthropometric and laboratory assessments***

All the participants completed a questionnaire about previous medical history, current medication, smoking habits, regular exercise, education level, and income. With regard to smoking, the participants were grouped as nonsmokers, past smokers, or current smokers.

From 2006 to 2007, the participants answered a questionnaire on the average quantity and frequency of alcohol consumption per week and type of alcohol during the previous 1-month period (31, 32) to minimize recall bias of the participants, our center chose the most recent previous 1-month period. The Quantity-Frequency (QF) questions on alcohol consumption within a given time frame are known to produce higher estimates than global QF questions (e.g., consumption during the entire year). From 2008 to 2009, participants chose the most recent period either previous 1-month or 1-week period. Synthetically, we produced weekly alcohol consumption by standard drink (approximately 12 grams of pure alcohol) of each participant.

With regard to previous medical history of hypertension, from 2006 to 2007 the participants was asked if they had current medication for hypertension, while from 2008 to 2009 the participants was asked if they had both diagnosed and taken medication. For the purpose of analysis participants were classified as either the normal or hypertension patients. Regarding diabetes, from 2006 to 2007 the participants was asked if they had been diagnosed or

not and if diabetes was well controlled or not while from 2008 to 2009 the participants was asked if they had been both diagnosed and taking medication. We classified the participants into simple two groups: the normal group or diabetes group.

Through 2006-2009, regular exercisers were defined if the participant answered if he or she regularly exercises, or if he or she had light, moderate, or vigorous activities for more than 30 minutes at least 3 times a week.

Height, weight, and weight circumference (WC) were measured, with the participants wearing light, single-thickness clothing, and standing erect with the feet together. WC was measured at the smallest circumference of the torso. BMI was calculated as the ratio of weight to the square of height ( $\text{kg}/\text{m}^2$ ). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in the left arm, with the participant in the sitting position after 5 minutes of rest.


Laboratory tests included serum calcium and phosphorus concentration, fasting blood sugar (FBS), total cholesterol (TC), triglyceride (TG), and high-density lipoprotein (HDL) cholesterol, serum creatinine, high sensitivity C-reactive protein (hs-CRP), and homocysteine after . The level of Non-HDL cholesterol was calculated:  $[\text{TC (mmol/L)} - \text{HDL cholesterol (mmol/L)}]$ . Serum HbA1c and insulin were also measured and recorded.

### ***Serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> measurement***

Serum was collected in serum separator tubes and the plasma was separated

by centrifugation and frozen at  $-70^{\circ}\text{C}$ .  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  was measured in thawed samples using a radioimmunoassay kit (Diasorin, Stillwater, MN, USA) which has a threshold of detection of 4 pg/mL. The Intra- and inter-assay coefficients of variation were 7.9% and 10.5%, respectively. We divided the participants into quintiles on the basis of total  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration and the lowest concentration group defaulted to the reference group. The seasonal distribution of  $1,25(\text{OH})_2$  vitamin by sex was described in Figure 2.

**Figure 2.** Seasonal distribution of 1,25 (OH)<sub>2</sub> vitamin D<sub>3</sub> concentration of study participants



### ***Measurement of carotid artery structure***

The ultrasonography of carotid arteries was performed while the subject was lying in the supine position with the head slightly extended using high-resolution B-mode ultrasound (IU22 Ultrasound System, Phillips, Eindhoven, the Netherlands) equipped with a 7.5MHz linear array transducer. Intima-media thickness was determined as the distance from the media-adventia interface to the intima-lumen interface on the posterior (far) wall (27). Qualified two radiologist evaluated three points of each common carotid artery free from advanced atherosclerotic lesion or plaque. The mean value of six measurements was determined as 'mean Common carotid artery (CCA)-IMT' diameter (33). Further, the radiologists also reported the presence and number of carotid plaques and carotid artery stenosis, and described the volume of plaques as three dimensional measure. The presence of plaques was defined as localized echo structures encroaching into the vessel lumen for which the wall thickening that was at least 50% greater than that of the surrounding vessel wall or greater than 1.5mm.

### ***Statistical analysis***

All analyses were performed using STATA statistical software version 12.0 (Stata Corp., College Station, TX, USA). Figure 3 and 4 shows that CCA IMT and  $25(\text{OH})_2$  vitamin D<sub>3</sub> distribution were both left skewed according to the Shapiro–Wilks test ( all  $p < 0.001$ ). The distributions of serum triglycerides




were left skewed. The clinical characteristics according to serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> status were evaluated with ANOVA to determine statistical differences in the continuous variables, and with  $\chi^2$  tests or Fisher's exact test for differences in the discrete variables. Pearson's correlation analysis was used in assessing the univariate associations between various risk factors and CCA-IMT.


We constructed an analysis of covariance (ANCOVA) model and linear models from the multivariate-adjusted mean areas of mean CCA-IMT, mean numbers and volumes of CCA plaque within the 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> categories. The model 1 was adjusted for age, BMI, regular exercise, cigarette smoking and weekly alcohol consumption, season of blood draw. The model 2 was further adjusted for the model 1 covariables and diabetes, hypertension, fasting glucose level, systolic blood pressure, serum total and Non-HDL cholesterol level. Model 3 was adjusted the aforementioned model 2 covariables and serum creatinine, calcium phosphorus level.

Furthermore, The association between 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> level and increased CCA IMT and occurrence of CCA plaques were assessed using multivariate logistic regression analyses. The adjusted models were constructed as three models as above.

**Figure 3.** Histogram of 1,25 (OH)<sub>2</sub> vitamin D<sub>3</sub> concentration of study participants



**Figure 4.** Distribution of mean CCA IMT of study participants



## Results

### *Baseline characteristics*

The characteristics of the male participants are presented in Table 1. The mean age, height, weight, WC were not significantly different across five quintile groups (all  $p>0.05$ ) while BMI decreased as 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration increased ( $p = 0.045$ ). The amount of weekly alcohol consumption increased as 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration increased ( $p<0.001$ ). Regular exercise, cigarette smoking, past history of diabetes and hypertension were not associated with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration (all  $p>0.05$ ). Serum calcium, total cholesterol and homocysteine level were shown to increase as with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> increased ( $p = 0.007$ ,  $0.002$  and  $0.014$ , respectively). Other laboratory tests results showed no statistical significance.

Table 2 showed that the characteristics of female participants. In female participants, 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration is more closely related to various factors than in male participants. The age of female participants tends to increase with increasing 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration ( $p<0.001$ ). The proportion of regular exercisers increased with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> increased ( $p<0.001$ ). Serum calcium and total cholesterol level increased according to 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration ( $p = 0.012$  and  $0.001$ , respectively) while serum non-HDL cholesterol showed marginal significance ( $p = 0.051$ ). Among female participants, CCA IMT tended to increase as

1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration increase, while occurrence of plaque decreased ( $p = 0.025$ ).

Season of blood draw showed statistically different according to 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration in female participants ( $p = 0.007$ ). Figure 2 showed histograms of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> by sex. Mean 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration was  $47.18 \pm 20.73$  pg/dl in male and  $38.22 \pm 16.79$  pg/dl in female participants ( $p < 0.001$  from T-test between two groups, Data not shown).

**Table 1.** Characteristics of study participants according to 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration in Men (n = 962)

Variables		Quintiles of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (median)						<i>p</i> <sup>a</sup>	<i>p</i> <sup>b</sup>
		Total	<32.0 (27.2) pg/ml	32.0-38.9 (35.1) pg/ml	39.0-46.8 (42.7) pg/ml	46.9-59.8 (51.7) pg/ml	>59.9 (73.6) pg/ml		
<i>N</i>	962		<i>n</i> = 193	<i>n</i> = 192	<i>n</i> = 193	<i>n</i> = 193	<i>n</i> = 191		
Age, yr	962	55.1 ± 10.3	54.7 ± 10.5	54.0 ± 11.5	55.4 ± 9.8	56.0 ± 10.0	55.3 ± 9.5	0.367	0.158
Height, cm	962	169.1 ± 6.0	168.3 ± 5.5	169.9 ± 6.4	169.2 ± 5.4	168.9 ± 5.9	169.1 ± 6.3	0.122	0.620
Weight, kg	962	72.0 ± 11.3	72.2 ± 11.5	73.5 ± 11.6	71.1 ± 10.4	72.1 ± 11.7	71.1 ± 11.3	0.212	0.170
BMI, kg/m <sup>2</sup>	962	25.1 ± 3.2	25.4 ± 3.5	25.3 ± 3.1	24.7 ± 3.1	25.2 ± 3.3	24.7 ± 3.1	0.110	0.045
WC, cm	962	89.4 ± 8.9	89.4 ± 9.0	90.4 ± 9.2	88.6 ± 8.4	89.6 ± 9.6	89.0 ± 8.4	0.361	0.456
Weekly alcohol intake (standard drink)	888	10.6 ± 15.1	6.9 ± 8.7	6.9 ± 9.5	10.2 ± 13.2	13.1 ± 17.8	16.1 ± 20.4	<0.001	<0.001
Regular exercise (n,%)	953	479 (50.2)	93 (48.6)	91 (48.1)	97 (50.5)	102 (53.6)	96 (50.2)	0.840	
Cigarette smoking (n,%)	935							0.081	
Never		213 (22.7)	52 (27.6)	39 (21.3)	44 (23.2)	45 (23.9)	33 (17.6)		
Past		420 (44.9)	80 (42.5)	86 (46.9)	97 (51.3)	74 (39.3)	83 (44.3)		
Current		302 (32.3)	56 (29.7)	58 (31.6)	48 (25.4)	69 (36.7)	71 (37.9)		
DM (n,%)	925	121 (13.1)	26 (14.0)	23 (12.5)	27 (14.4)	24 (12.8)	21 (11.5)	0.924	
HTN (n,%)	934	268 (28.6)	50 (26.7)	47 (25.5)	59 (30.8)	59 (30.8)	53 (28.8)	0.670	
SBP (mmHg)	962	131.7 ± 15.6	131.8 ± 18.0	130.1 ± 16.0	131.3 ± 14.9	131.9 ± 14.2	133.6 ± 14.6	0.278	0.120
DBP (mmHg)	962	80.1 ± 11.0	80.1 ± 12.7	78.9 ± 10.4	79.3 ± 10.5	80.5 ± 10.5	81.7 ± 10.4	0.095	0.056
FBS (mg/dL)	962	98.1 ± 23.3	97.0 ± 20.7	96.7 ± 24.4	99.0 ± 22.9	98.9 ± 23.8	99.0 ± 24.6	0.754	0.245
Calcium	962	9.22 ± 0.34	9.15 ± 0.35	9.23 ± 0.34	9.21 ± 0.33	9.24 ± 0.35	9.28 ± 0.31	0.007	0.001
Phosphorus	962	3.26 ± 0.46	3.26 ± 0.51	3.26 ± 0.41	3.26 ± 0.43	3.25 ± 0.46	3.29 ± 0.47	0.903	0.503
HbA1c (%)	962	5.93 ± 0.75	5.92 ± 0.78	5.93 ± 0.79	5.94 ± 0.70	5.95 ± 0.75	5.91 ± 0.75	0.990	0.988
Insulin (μIU/ml)	945	10.22 ± 4.94	9.96 ± 4.79	10.19 ± 4.54	10.19 ± 4.76	10.64 ± 6.00	10.11 ± 4.48	0.741	0.512
Total Cholesterol (mg/dL)	962	200.5 ± 34.0	193.0 ± 33.1	199.8 ± 32.2	199.5 ± 36.4	205.2 ± 28.7	205.0 ± 37.6	0.002	<0.001
Non-HDL cholesterol (mg/dL)	962	150.3 ± 34.4	145.4 ± 34.0	151.3 ± 32.6	149.3 ± 36.5	153.7 ± 28.5	151.6 ± 39.1	0.173	0.059

Creatinine (mg/dL)	962	1.09 ± 0.17	1.09 ± 0.27	1.08 ± 0.13	1.09 ± 0.15	1.09 ± 0.14	1.09 ± 0.15	0.984	0.851
hs-CRP (mg/L)	917	0.19 ± 0.52	0.29 ± 0.85	0.14 ± 0.28	0.18 ± 0.50	0.17 ± 0.30	0.18 ± 0.41	0.086	0.113
Homocysteine (umol/L)	934	11.0 ± 3.1	11.1 ± 2.7	11.0 ± 2.4	11.3 ± 2.4	11.3 ± 3.2	12.0 ± 3.5	0.014	0.003
IMT, mm	962	0.70 ± 0.15	0.70 ± 0.14	0.71 ± 0.21	0.69 ± 0.12	0.71 ± 0.14	0.69 ± 0.14	0.377	0.480
IMT ≥ 0.75 mm (n,%)	962	329 (34.2)	73 (37.8)	64 (33.3)	66 (34.2)	63 (32.6)	63 (32.9)	0.822	
IMT ≥ 0.90 mm (n,%)	962	85 (8.8)	17 (8.8)	22 (10.9)	12 (6.2)	19 (9.8)	16 (8.3)	0.560	
Presence of plaque (n,%)	951	152 (15.9)	29 (15.0)	27 (14.2)	32 (16.7)	28 (14.8)	36 (19.0)	0.711	
No of plaque	951	0.25 ± 0.69	0.22 ± 0.61	0.20 ± 0.55	0.26 ± 0.74	0.26 ± 0.78	0.30 ± 0.77	0.377	0.159
Volume of plaque, mm <sup>3</sup>	915	20.9 ± 199.1	16.5 ± 87.4	6.1 ± 31.2	17.3 ± 123.3	15.4 ± 79.2	50.0 ± 415.3	0.271	0.106
Season of measurement (n,%)	962							0.418	
Spring (mar to may)		225 (23.3)	52 (26.9)	44 (22.9)	52 (26.9)	35 (24.8)	41 (21.4)		
Summer (Jun to Aug)		224 (23.2)	50 (25.9)	50 (26.0)	51 (26.4)	55 (28.5)	54 (28.2)		
Fall (Sep to Nov)		260 (27.0)	39 (20.2)	51 (26.5)	50 (25.9)	55 (28.5)	58 (30.3)		
Winter (Dec to Feb)		253 (26.3)	52 (26.9)	47 (24.4)	40 (20.7)	48 (24.8)	38 (19.9)		

Data are presented as the means and standard deviation [SD], or number and percentages

<sup>a</sup>p value from ANOVA for continuous variables or chi-squared test for categorical variables.

<sup>b</sup>p value from linear regression analysis

<sup>c</sup>p value from Fisher's exact test

Abbreviations: BMI, body mass index; WC, waist circumference; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; CRP, C-reactive protein; IMT, intima-media thickness

**Table 2.** Characteristics of study participants according to 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration in Women (n = 853)

	n	Total	Quintiles of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (median)					<i>p</i> <sup>a</sup>	<i>p</i> <sup>b</sup>
			<25.5 (21.4) pg/ml <i>n</i> = 171	25.5-31.7 (28.7) pg/ml <i>n</i> = 173	31.8-38.8 (35.0) pg/ml <i>n</i> = 169	38.9-48.5 (51.7) pg/ml <i>n</i> = 170	>48.6 (59.1) pg/ml <i>n</i> = 170		
<i>N</i>	853								
Age, yr	853	53.9 ± 10.2	53.9 ± 10.2	54.9 ± 10.2	55.4 ± 8.2	57.2 ± 8.5	58.9 ± 8.5	<0.001	<0.001
Height, cm	853	156.3 ± 5.3	156.5 ± 4.9	156.3 ± 5.7	156.2 ± 5.3	156.9 ± 5.1	155.4 ± 5.3	0.143	0.240
Weight, kg	853	58.9 ± 9.1	58.5 ± 10.0	59.6 ± 9.8	59.8 ± 9.1	59.4 ± 8.3	57.1 ± 7.7	0.035	0.178
BMI, kg/m <sup>2</sup>	853	24.1 ± 3.4	23.8 ± 3.8	24.4 ± 3.8	24.5 ± 3.5	24.1 ± 3.2	23.6 ± 2.8	0.102	0.366
WC, cm	853	85.7 ± 9.2	84.5 ± 9.3	86.2 ± 9.3	86.4 ± 9.5	86.3 ± 9.1	85.3 ± 8.8	0.225	0.424
Weekly alcohol intake (standard drink)	750	1.2 ± 5.6	1.0 ± 4.4	1.0 ± 3.7	0.8 ± 2.4	0.7 ± 2.3	2.3 ± 10.5	0.098	0.118
Regular exercise (n,%)	838	378 (45.1)	58 (34.5)	73 (42.4)	73 (43.7)	80 (48.4)	94 (56.6)	<0.001	
Cigarette smoking (n,%)	796							0.401	
Never		740 (93.0)	136 (88.8)	151 (94.9)	143 (92.2)	158 (95.1)	152 (93.2)		
Past		27 (3.4)	10 (6.5)	3 (1.8)	6 (3.8)	4 (2.4)	4 (2.4)		
Current		29 (3.6)	7 (4.5)	5 (3.1)	6 (3.8)	4 (2.4)	7 (4.2)		
DM (n,%)	804	52 (6.4)	9 (5.7)	7 (4.3)	10 (6.2)	12 (7.3)	14 (8.5)	0.594	
HTN (n,%)	823	196 (23.8)	35 (21.4)	35 (21.4)	38 (23.3)	37 (22.2)	51 (30.7)	0.222	
SBP (mmHg)	853	128.2 ± 17.3	126.2 ± 15.9	129.8 ± 17.7	126.5 ± 16.1	128.4 ± 18.8	130.1 ± 17.6	0.124	0.134
DBP (mmHg)	853	76.7 ± 10.6	76.1 ± 10.3	77.3 ± 10.6	76.1 ± 10.7	76.9 ± 11.2	77.1 ± 10.5	0.777	0.562
FBS (mg/dL)	853	92.5 ± 17.2	91.2 ± 15.8	92.9 ± 18.1	91.9 ± 14.9	92.7 ± 18.3	93.7 ± 18.4	0.732	0.269
Calcium	853	9.20 ± 0.38	9.12 ± 0.39	9.18 ± 0.35	9.23 ± 0.37	9.24 ± 0.38	9.20 ± 0.38	0.026	0.012
Phosphorus	853	3.72 ± 0.55	3.70 ± 0.66	3.69 ± 0.57	3.74 ± 0.49	3.77 ± 0.51	3.69 ± 0.52	0.631	0.713
HbA1c (%)	853	5.85 ± 0.60	5.84 ± 0.60	5.83 ± 0.53	5.83 ± 0.60	5.85 ± 0.70	5.90 ± 0.56	0.778	0.312
Insulin (μU/ml)	825	9.91 ± 4.05	9.63 ± 4.43	10.32 ± 4.59	9.85 ± 3.81	10.20 ± 3.84	9.53 ± 3.47	0.309	0.741
Total Cholesterol (mg/dL)	853	206.8 ± 37.3	198.0 ± 31.2	205.0 ± 40.3	212.6 ± 38.2	206.1 ± 37.0	212.3 ± 37.5	0.001	0.001
Non-HDL cholesterol (mg/dL)	853	148.3 ± 36.7	142.2 ± 32.0	148.0 ± 39.1	153.9 ± 37.3	147.1 ± 36.0	150.4 ± 38.1	0.051	0.084



Creatinine (mg/dL)	853	0.86 ± 0.12	0.84 ± 0.14	0.87 ± 0.10	0.86 ± 0.10	0.88 ± 0.13	0.86 ± 0.09	0.012	0.089
hs-CRP (mg/L)	811	0.14 ± 0.44	0.16 ± 0.42	0.12 ± 0.27	0.09 ± 0.14	0.13 ± 0.22	0.19 ± 0.82	0.298	0.529
Homocysteine (umol/L)	820	8.51 ± 2.66	8.53 ± 3.79	8.35 ± 2.02	8.39 ± 2.10	8.79 ± 3.06	8.49 ± 1.79	0.595	0.591
IMT, mm	853	0.65 ± 0.11	0.62 ± 0.11	0.65 ± 0.10	0.65 ± 0.11	0.66 ± 0.12	0.67 ± 0.10	0.005	<0.001
IMT ≥ 0.75 mm (n,%)	853	157 (18.4)	24 (14.0)	26 (15.0)	33 (19.5)	34 (20.0)	40 (23.5)	0.142	
IMT ≥ 0.90 mm (n,%)	853	32 (3.7)	5 (2.9)	6 (3.4)	5 (2.8)	8 (4.7)	8 (4.7)	0.848 <sup>c</sup>	
Presence of plaque (n,%)	839	86 (10.2)	23 (13.8)	15 (8.7)	12 (7.1)	11 (6.5)	25 (15.0)	0.025 <sup>c</sup>	
No of plaque	839	0.14 ± 0.47	0.17 ± 0.47	0.12 ± 0.44	0.10 ± 0.38	0.07 ± 0.28	0.24 ± 0.67	0.010	0.515
Volume of plaque, mm <sup>3</sup>	839	5.1 ± 53.3	13.2 ± 112.7	3.4 ± 17.4	0.9 ± 6.3	0.9 ± 4.6	7.5 ± 36.4	0.180	0.297
Season of measurement (n,%)	853							0.007	
Spring (mar to may)		225 (23.3)	50 (29.2)	48 (27.7)	37 (21.8)	29 (17.0)	27 (15.8)		
Summer (Jun to Aug)		224 (23.2)	50 (29.2)	45 (26.0)	51 (30.1)	48 (28.2)	48 (28.2)		
Fall (Sep to Nov)		260 (27.0)	34 (19.8)	39 (22.5)	48 (28.4)	63 (37.0)	60 (35.2)		
Winter (Dec to Feb)		253 (26.3)	37 (21.6)	41 (23.7)	33 (19.5)	30 (17.6)	35 (20.5)		

Data are presented as the means and standard deviation [SD], or number and percentages

<sup>a</sup>p value from ANOVA for continuous variables or chi-squared test for categorical variables.

<sup>b</sup>p value from linear regression analysis

<sup>c</sup>p value from Fisher's exact test

Abbreviations: BMI, body mass index; WC, waist circumference; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; CRP, C-reactive protein; IMT, intima-media thickness

***Univariate Correlations of various cardiovascular risk factors and mean CCA-IMT***

As shown in Table 3, mean CCA-IMT was correlated with various variables of cardiovascular risk factors particularly among women. In men, mean CCA-IMT showed significant positive correlations with age, SBP, FBS, serum creatinine, and homocysteine while negatively correlated with weekly alcohol intake and serum calcium level. In women, mean CCA-IMT showed significant positive correlations with age, BMI, WC, SBP, DBP, FBS, HbA1c, total cholesterol, serum phosphorus, homocysteine and serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration.

**Table 3.** Pearson' s correlation coefficients for univariate associations between various risk factors and mean CCA IMT.

	Men		Women	
	<i>r</i>	P value	<i>r</i>	P value
Age	0.439*		0.460*	<0.001
BMI	-0.033		0.164*	<0.001
WC (cm)	0.001	0.952	<0.001	<0.001
Weekly alcohol intake (standard drink)	-0.074*	0.026	0.293	0.7068
SBP (mmHg)	0.078*	0.014	0.214*	<0.001
DBP (mmHg)	-0.020	0.534	0.105*	0.002
FBS (mg/dL)	0.070*	0.029	0.174*	<0.001
HbA1c (%)	0.116	<0.001	0.191*	<0.001
Insulin ( $\mu$ IU/ml)	-0.028	0.376	0.061	0.077
Total Cholesterol (mg/dL)	-0.037	0.250	0.168*	<0.001
Non-HDL cholesterol (mg/dL)	-0.011	0.717	0.195*	<0.001
Calcium	-0.071*	0.027	-0.010	0.750
Phosphorus	-0.001	0.970	0.107*	0.001
Creatinine (mg/dl)	0.110*	<0.001	0.039	0.250
hs-CRP (mg/l)	0.023	0.479	0.046	0.188
Homocysteine (umol/L)	0.089*	0.006	0.072*	0.037
1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (pg/mL)	-0.043	0.179	0.099*	0.003

Abbreviations: BMI, body mass index; WC, waist circumference; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; CRP, C-reactive protein; IMT, intima-media thickness

***The associations between 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and Carotid atherosclerosis indexes***

In ANCOVA, CCA IMT was not associated with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration both in male and in female participants (Table 4 and 5). The R square values were 0.23 in Model 1, 0.24 in model 2, 0.26 in model 3 in men (Table 4) while the value were 0.24 in Model 1, 0.25 in model 2, 0.26 in model 3 in women (Table 5) analyzing CCA IMT with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration.

In women, numbers and volume of CCA plaques were significantly associated with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration (Table 5). The association showed the J or U shape. In the concentration of 3rd quintile (31.8-38.8 pg/ml) and 4th quintile (38.9-48.5 pg/ml), decreased number and volume of CCA plaque were demonstrated ( $p=0.022$  and  $0.023$  for number of CCA plaque, and  $p=0.030$  and  $0.020$  for volume of CCA plaque in Model 3, respectively). In the concentration of 5th quintile, no significant difference compared with the reference group of 1st quintile ( $p=0.571$  for number of CCA plaque, and  $p=0.063$  for volume of CCA plaque in Model 3, respectively).

In men, numbers and volume of CCA plaques were not significantly associated with 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration, although volume

of CCA plaque showed slightly J shaped association with  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration (Table 4).

In multivariate logistic regression analyses for binary outcomes, male participants showed no significant results in increased CCA IMT and CCA plaques (Table 6). But in female participants in Table 7, a reverse J-shaped relationship was reported. There was significantly decreased occurrence of CCA plaque was reported in 3rd quintile ( $p=0.011$  in Model 3) 4th quintile ( $p=0.036$  in Model 3). We found marginally significant decrease in 2nd quintile ( $p=0.059$  in Model 3), however, no significant decrease or increase in 5th quintile ( $p=0.206$  in Model 3).

**Table 4.** Mean values of carotid indexes of participants according to of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration in men (n = 962).

		Quintiles of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (Median)					<i>p</i> value <sup>a</sup>
		<32.0 (27.2) pg/ml <i>n</i> = 193	32.0-38.9 (35.1) pg/ml <i>n</i> = 192	39.0-46.8 (42.7) pg/ml <i>n</i> = 193	46.9-59.8 (51.7) pg/ml <i>n</i> = 193	>59.9 (73.6) pg/ml <i>n</i> = 191	
CCA IMT	Model 1	0.703 (0.009)	0.718 (0.009)	0.696 (0.009)	0.706 (0.009)	0.702 (0.009)	0.630
	Model 2	0.700 (0.009)	0.711 (0.009)	0.696 (0.009)	0.704 (0.009)	0.706 (0.009)	0.831
	Model 3	0.700 (0.009)	0.712 (0.009)	0.696 (0.009)	0.704 (0.009)	0.706 (0.009)	0.815
Number of CCA plaques	Model 1	0.220 (0.052)	0.246 (0.053)	0.260 (0.052)	0.263 (0.051)	0.303 (0.053)	0.868
	Model 2	0.209 (0.053)	0.222 (0.053)	0.258 (0.052)	0.264 (0.051)	0.275 (0.051)	0.898
	Model 3	0.207 (0.053)	0.222 (0.054)	0.258 (0.052)	0.264 (0.051)	0.275 (0.051)	0.893
Volume of CCA plaques	Model 1	20.057 (16.325)	10.164 (16.682)	17.568 (16.515)	12.120 (15.977)	52.158 (16.848)	0.385
	Model 2	21.321 (17.077)	9.059 (17.210)	18.373 (17.069)	11.575 (16.393)	53.543 (17.608)	0.379
	Model 3	22.277 (17.147)	9.191 (17.243)	18.455 (17.103)	11.157 (16.423)	52.789 (17.703)	0.400

*Note:* Values are mean (s.e.) adjusted for multiple variables

Model 1: Values are odds ratios adjusted for age, BMI, regular exercise, cigarette smoking and weekly alcohol consumption, season of blood draw.

Model 2: Values are odds ratios adjusted for covariables of Model 1 + diabetes, hypertension, serum total and Non-HDL cholesterol level, fasting glucose level and systolic blood pressure.

Model 3: Values are odds ratios adjusted for covariables of Model 2 + serum creatinine level, calcium level and phosphorus level.

<sup>a</sup>*P* value from ANCOVA according to 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration

**Table 5.** Mean values of carotid indexes of participants according to of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration in women (n = 853).

N		Quintiles of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (median)					p value <sup>b</sup>
		<25.5 (21.4) pg/ml n = 171	25.5-31.7 (28.7) pg/ml n = 173	31.8-38.8 (35.0) pg/ml n = 169	38.9-48.5 (51.7) pg/ml n = 170	>48.6 (59.1) pg/ml n = 170	
CCA IMT	Model 1	0.644 (0.008)	0.656 (0.008)	0.656 (0.008)	0.661 (0.008)	0.659 (0.008)	0.620
	Model 2	0.644 (0.008)	0.655 (0.008)	0.654 (0.009)	0.662 (0.008)	0.660 (0.008)	0.620
	Model 3	0.642 (0.008)	0.655 (0.008)	0.655 (0.008)	0.661 (0.008)	0.660 (0.008)	0.526
Number of CCA plaques	Model 1	0.201 (0.038)	0.117 (0.037)	0.078 (0.037)*	0.066 (0.037)*	0.186 (0.037)	0.031
	Model 2	0.200 (0.038)	0.118 (0.037)	0.072 (0.037)*	0.070 (0.037)*	0.169 (0.037)	0.052
	Model 3	0.198 (0.038)	0.118 (0.037)	0.073 (0.037)*	0.073 (0.037)*	0.166 (0.038)	0.075
Volume of CCA plaques (mm <sup>3</sup> )	Model 1	16.863 (4.964)	3.242 (4.815)	1.128 (4.862)*	0.579 (4.807)*	3.476 (4.921)	0.119
	Model 2	17.149 (5.178)	3.336 (4.963)	1.273 (5.024)*	0.499 (4.998)*	3.182 (5.100)	0.137
	Model 3	17.225 (5.207)	3.243 (4.966)	1.453 (5.030)*	0.126 (5.021)*	3.397 (5.109)	0.135

Note: Values are mean (s.e.) adjusted for multiple variables

Model 1: Values are odds ratios adjusted for age, BMI, regular exercise, cigarette smoking and weekly alcohol consumption, season of blood draw.

Model 2: Values are odds ratios adjusted for covariables of Model 1 + diabetes, hypertension, serum total and Non-HDL cholesterol level, fasting glucose level and systolic blood pressure.

Model 3: Values are odds ratios adjusted for covariables of Model 2 + serum creatinine level, calcium level and phosphorus level.

<sup>a</sup>P value from ANCOVA according to 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration

\*P value <0.05 compared with the reference group

**Table 6.** Association of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and increased carotid atherosclerosis in men (n = 962).

		Quintiles of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (Median)					<i>p</i> value <sup>b</sup>
		<32.0 (27.2) pg/ml <i>n</i> = 193	32.0-38.9 (35.1) pg/ml <i>n</i> = 192	39.0-46.8 (42.7) pg/ml <i>n</i> = 193	46.9-59.8 (51.7) pg/ml <i>n</i> = 193	>59.9 (73.6) pg/ml <i>n</i> = 191	
CCA IMT ≥ 0.75 mm	Model 1	1	0.87 (0.53–1.44)	0.97 (0.59–1.58)	0.68 (0.42–1.13)	0.91 (0.55–1.51)	0.463
	Model 2	1	0.95 (0.56–1.77)	1.06 (0.64–1.77)	0.76 (0.45–1.28)	1.10 (0.65–1.86)	0.949
	Model 3	1	0.96 (0.57–1.63)	1.07 (0.64–1.78)	0.77 (0.46–1.30)	1.11 (0.65–1.89)	0.979
CCA IMT ≥ 0.90 mm	Model 1	1	1.33 (0.61–2.90)	0.77 (0.32–1.81)	1.05 (0.48–2.29)	1.01 (0.45–2.29)	0.810
	Model 2	1	1.28 (0.56–2.92)	0.83 (0.35–2.00)	1.13 (0.50–2.58)	1.17 (0.50–2.73)	0.839
	Model 3	1	1.27 (0.55–2.91)	0.83 (0.34–1.99)	1.09 (0.47–2.51)	1.15 (0.49–2.71)	0.899
Occurrence of CCA plaque	Model 1	1	1.05 (0.55–1.99)	1.12 (0.60–2.08)	0.91 (0.49–1.71)	1.22 (0.66–2.26)	0.688
	Model 2	1	0.92 (0.47–1.82)	1.16 (0.61–2.19)	0.91 (0.47–1.76)	1.10 (0.57–2.11)	0.807
	Model 3	1	0.95 (0.48–2.23)	1.17 (0.61–2.23)	0.94 (0.48–1.82)	1.12 (0.58–2.16)	0.778

Model 1: Values are odds ratios adjusted for age, BMI, regular exercise, cigarette smoking and weekly alcohol consumption, season of blood draw.

Model 2: Values are odds ratios adjusted for covariables of Model 1 + diabetes, hypertension, serum total and Non-HDL cholesterol level, fasting glucose level and systolic blood pressure.

Model 3: Values are odds ratios adjusted for covariables of Model 2 + serum creatinine level, calcium level and phosphorus level.



**Table 7.** Association of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and increased carotid atherosclerosis in women (n = 853).

		Quintiles of 1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> (median)					<i>p</i> value <sup>b</sup>
		<25.5 (21.4) pg/ml <i>n</i> = 171	25.5-31.7 (28.7) pg/ml <i>n</i> = 173	31.8-38.8 (35.0) pg/ml <i>n</i> = 169	38.9-48.5 (51.7) pg/ml <i>n</i> = 170	>48.6 (59.1) pg/ml <i>n</i> = 170	
CCA IMT ≥ 0.75 mm	Model 1	1	0.85 (0.42–1.74)	1.18 (0.60–2.33)	0.97 (0.49–1.91)	1.20 (0.62–2.33)	0.483
	Model 2	1	0.81 (0.39–1.69)	1.16 (0.58–2.35)	0.97 (0.47–1.96)	1.21 (0.61–2.40)	0.433
	Model 3	1	0.92 (0.44–1.33)	1.33 (0.65–2.72)	1.07 (0.51–2.22)	1.37 (0.68–2.76)	0.298
CCA IMT ≥ 0.90 mm	Model 1	1	0.98 (0.24–3.99)	0.90 (0.21–3.84)	1.40 (0.38–5.12)	1.36 (0.37–4.88)	0.474
	Model 2	1	1.13 (0.27–4.77)	0.66 (0.13–3.30)	1.70 (0.43–6.67)	1.49 (0.39–5.67)	0.402
	Model 3	1	1.67 (0.36–7.66)	1.03 (0.19–5.59)	2.61 (0.60–11.41)	2.09 (0.50–8.74)	0.239
Occurrence of CCA plaque	Model 1	1	0.44 (0.19–1.03)	0.30 (0.11–0.78)*	0.37 (0.16–0.88)*	0.65 (0.31–1.38)	0.320
	Model 2	1	0.41 (0.17–1.00)	0.25 (0.09–0.71)*	0.37 (0.15–0.90)*	0.59 (0.26–1.30)	0.268
	Model 3	1	0.42 (0.17–1.03)	0.26 (0.09–0.74)*	0.38 (0.15–0.94)*	0.59 (0.26–1.32)	0.299

Model 1: Values are odds ratios adjusted for age, BMI, regular exercise, cigarette smoking and weekly alcohol consumption, season of blood draw.

Model 2: Values are odds ratios adjusted for covariables of Model 1 + diabetes, hypertension, serum total and Non-HDL cholesterol level, fasting glucose level and systolic blood pressure.

Model 3: Values are odds ratios adjusted for covariables of Model 2 + serum creatinine level, calcium level and phosphorus level.

\**P* value <0.05

## Discussion

In the present study, male participants showed mean CCA-IMT level of  $0.70 \pm 0.15$  mm and female participants showed the level of  $0.65 \pm 0.11$  mm, which correspond to previous study of healthy Koreans' IMT with the value of  $0.66 \pm 0.11$  mm (34). Mean  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration,  $47.18 \pm 20.73$  pg/dl in male and  $38.22 \pm 16.79$  pg/dl, does also correspond to the level of previous population-based studies (30, 35). We found significant associations between serum  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration and plaque of CCA only in women. Adequate serum  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration is associated with decreased occurrence of carotid plaques, numbers and volumes of carotid plaques. And these associations seem to be J-shape or U shape suggesting that there could be a threshold of vitamin D concentration adequate for decreasing subclinical cardiovascular diseases. The lowest risk of plaque seemed to be with the levels between 31.8 and 48.5 pg/ml of  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  independently of other factors.

In the present study, we had used serum  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration instead of  $25(\text{OH})$  vitamin  $\text{D}_3$ .  $25(\text{OH})$  vitamin  $\text{D}_3$  requires additional hydroxylation by 1- $\alpha$ -hydroxylase to become active  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$ . The half-life of  $25(\text{OH})$  vitamin  $\text{D}_3$  in the circulation is 2 weeks, whereas the half-life of its active metabolite is less than 4 hours. The concentration of  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  is 1000-fold lower than that of  $25(\text{OH})$  vitamin  $\text{D}_3$ .

Therefore, guideline does not recommend 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> as a screening tool for vitamin D deficiency (18). However, previous studies showed low 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> is also independently associated with cardiovascular outcomes (30, 36), and 25(OH) vitamin D<sub>3</sub> is a predictor of serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> (37). One study suggest 25 (OH) vitamin D<sub>3</sub> and 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> levels may yield similar but independent biologic effects for cardiovascular outcomes (30). Another study found 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> showed strong association with renal outcome more than 25 (OH) vitamin D<sub>3</sub> did (36).

Up to now, optimal levels of vitamin D have not been fully established. Regarding cardiovascular mortality, Durup et al. (20) and Hutchinson et al. (19) suggest that a U-shaped or J-shaped association between 25 (OH) vitamin D<sub>3</sub> and all-cause mortality with the optimal 25 (OH) vitamin D<sub>3</sub> level of approximately 50 – 75 nmol/Liter (=24 – 32 ng/mL, to convert to nanogram per milliliter, divide by 2.496). This level seem to correspond to the level of 31 – 50 ng/mL of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> according to the previous study (30), which is similar to the level of decreasing carotid plaque in the present study.

Koreans usually consumes vitamin D far lesser, as low as 6 ug (38), than Recommended Daily Allowance (RDA). RDA for vitamin D intake is the level of 15ng (600IU) in young and middle-aged subjects, and recommendations for diseased patients at risk for vitamin D deficiency is

widely-ranged from 37.5ng (1500IU) to 50ng (2000IU) (18). There should be more evidences for adequate intake of vitamin D preventing cardiovascular diseases.

We found the lowest vitamin D level is associated with subclinical atherosclerosis only in female participants. Allegedly, vitamin D insufficiency is more prevalent in women across the world (39-42). In Korea, vitamin D insufficiency (25(OH) vitamin D<sub>3</sub> <20 mg/dL) was found in 47.3% of males and 64.5% of females of general population (43). It is Not only in its epidemiology, but also in its effect, that some studies suggest there is a gender difference of vitamin D. Correale et al. suggest that there is estrogen-promoted differences in vitamin D<sub>3</sub> metabolism and there be a greater protective effect of vitamin D of immunomodulation in women (44). Estrogen stimulates 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> accumulation during ovulation and pregnancy, when its levels are high, and active vitamin D<sub>3</sub> levels increase in postmenopausal women receiving estrogen therapy (45-47). Treating osteoporosis, a synergistic effect between vitamin D<sub>3</sub> and estrogen on increasing bone mineral density has been reported (48). There should be more evidences about gender difference of effect of vitamin D in cardiovascular health.

Carotid ultrasonography is an early and effective marker of onset of cardiovascular diseases which is being real-time, economic, reliable, safe, and now seems to become a standard in vascular assessment methodology (26, 27).

Measurement of carotid plaque is more strongly predictive of cardiovascular events than is measurement of carotid intima-media thickness (IMT) (28, 49). In the present study, we found significant association only in CCA plaque. Recently, Inaba et al. suggested that Diffuse adaptive thickening of carotid wall (measured by CCA-IMT) as a response to ageing and hypertension rather reflects arteriosclerosis than plaque formation, which is a focal process and carotid plaque is more related to atherosclerotic processes such as inflammation, oxidation and endothelial dysfunction (28). Also, the genetic determinants of carotid IMT and carotid plaques may differ (50). Vitamin D mechanism is more related to atherosclerotic processes such as inflammation, oxidation and endothelial dysfunction rather than aging and hypertension (12, 16), therefore, our present study is comparable to those previous results.

Our study has several limitations. First, this study was cross-sectional. Thus, we could not establish a cause-and-effect relationship between serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration and carotid atherosclerosis. Future longitudinal studies of vitamin D and carotid atherosclerosis are needed. Second, through 2006-2007, health questionnaire survey did not include questions about current medication for hyperlipidemia. Although we controlled total cholesterol and Non-HDL cholesterol level, which could introduce bias. Third, we were unable to evaluate sun exposure exactly, because we do not include survey about weather condition of the survey day and sunscreens the participants might use. Fourth, as aforementioned, We

used serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> concentration instead of 25(OH) vitamin D<sub>3</sub>, which has short half-life. As mentioned above, serum 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> has a short half-life and hard to measure.

## Conclusions

In the present study, low  $1,25(\text{OH})_2$  vitamin  $\text{D}_3$  concentration showed a significant association with increased risk of carotid plaque independent of other factors, implying that low vitamin D alters vascular metabolism. Moreover, the results of present study indicate that adequate vitamin D concentration, not too low or too high level, is associated with decrease of subclinical carotid plaques among Korean women, but not among Korean men. Interventions targeting healthy individuals with lower or higher level of vitamin D may be needed. Our results will be a useful reference for further assessments of vitamin D status.

## References

1. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. *Am J Clin Nutr*. 2008;88(6):1519-27. Epub 2008/12/10.
2. Lim SK, Kung AW, Sompongse S, Soontrapa S, Tsai KS. Vitamin D inadequacy in postmenopausal women in Eastern Asia. *Current medical research and opinion*. 2008;24(1):99-106. Epub 2007/11/22.
3. Renzaho AM, Halliday JA, Nowson C. Vitamin D, obesity, and obesity-related chronic disease among ethnic minorities: a systematic review. *Nutrition*. 2011;27(9):868-79. Epub 2011/06/28.
4. Vaidya A, Forman JP. Vitamin D and hypertension: current evidence and future directions. *Hypertension*. 2010;56(5):774-9. Epub 2010/10/13.
5. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. *Diabetes care*. 2011;34(5):1081-5. Epub 2011/04/29.
6. Deleskog A, Hilding A, Brismar K, Hamsten A, Efendic S, Ostenson CG. Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. *Diabetologia*. 2012;55(6):1668-78. Epub 2012/03/20.
7. Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. *Preventive medicine*. 2010;51(3-4):228-33. Epub 2010/07/06.
8. Kojima G, Bell C, Abbott RD, Launer L, Chen R, Motonaga H, et al. Low dietary vitamin D predicts 34-year incident stroke: the Honolulu Heart Program. *Stroke*. 2012;43(8):2163-7. Epub 2012/05/26.
9. Pilz S, Tomaschitz A, Marz W, Drechsler C, Ritz E, Zittermann A, et al. Vitamin D, cardiovascular disease and mortality. *Clin Endocrinol (Oxf)*. 2011;75(5):575-84. Epub 2011/06/21.
10. Holick MF. Vitamin D deficiency. *The New England journal of medicine*. 2007;357(3):266-81. Epub 2007/07/20.
11. Battault S, Whiting SJ, Peltier SL, Sadrin S, Gerber G, Maixent JM. Vitamin D metabolism, functions and needs: from science to health claims. *European journal of nutrition*. 2012. Epub 2012/08/14.
12. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. *Journal of the American Society of Nephrology : JASN*. 2002;13(3):621-9. Epub 2002/02/22.
13. Chen S, Gardner DG. Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. *The Journal of steroid biochemistry*



- and molecular biology. 2012. Epub 2012/09/20.
14. Manna P, Jain SK. Vitamin D upregulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-gamma-lyase (CSE) activation and H<sub>2</sub>S formation in 3T3L1 adipocytes. *The Journal of biological chemistry*. 2012. Epub 2012/10/18.
  15. Yin Y, Yu Z, Xia M, Luo X, Lu X, Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. *European journal of clinical investigation*. 2012;42(11):1189-96. Epub 2012/09/11.
  16. Riek AE, Oh J, Sprague JE, Timpson A, de Las Fuentes L, Bernal-Mizrachi L, et al. Vitamin D Suppression of Endoplasmic Reticulum Stress Promotes an Anti-Atherogenic Monocyte/Macrophage Phenotype in Type 2 Diabetic Patients. *The Journal of biological chemistry*. 2012. Epub 2012/09/27.
  17. Zittermann A. Serum 25-hydroxyvitamin D response to oral vitamin D intake in children. *Am J Clin Nutr*. 2003;78(3):496-7. Epub 2003/08/26.
  18. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96(7):1911-30. Epub 2011/06/08.
  19. Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromso study. *European journal of endocrinology / European Federation of Endocrine Societies*. 2010;162(5):935-42. Epub 2010/02/27.
  20. Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. *J Clin Endocrinol Metab*. 2012;97(8):2644-52. Epub 2012/05/11.
  21. Newman WP, 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. *The New England journal of medicine*. 1986;314(3):138-44. Epub 1986/01/16.
  22. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *JAMA : the journal of the American Medical Association*. 1990;264(23):3018-24. Epub 1990/12/19.
  23. Sabanayagam C, Shankar A, Somasundaram S. Serum vitamin D level and prehypertension among subjects free of hypertension. *Kidney & blood pressure research*. 2012;35(2):106-13. Epub 2011/09/22.
  24. Gonzalez-Molero I, Rojo-Martinez G, Morcillo S, Gutierrez-Repiso C, Rubio-Martin E, Almaraz MC, et al. Vitamin D and incidence of diabetes: A prospective cohort study. *Clin Nutr*. 2011. Epub 2011/12/30.
  25. Husemoen LL, Skaaby T, Thuesen BH, Jorgensen T, Fenger RV,

- Linneberg A. Serum 25(OH)D and incident type 2 diabetes: a cohort study. *European journal of clinical nutrition*. 2012. Epub 2012/10/04.
26. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. *Circulation*. 1997;96(5):1432-7. Epub 1997/10/07.
27. Molinari F, Zeng G, Suri JS. A state of the art review on intima-media thickness (IMT) measurement and wall segmentation techniques for carotid ultrasound. *Computer methods and programs in biomedicine*. 2010;100(3):201-21. Epub 2010/05/19.
28. Inaba Y, Chen JA, Bergmann SR. Carotid Plaque, Compared with Carotid Intima-Media Thickness, More Accurately Predicts Coronary Artery Disease Events: A Meta-Analysis. *Circulation*. 2011;124(21).
29. Plichart M, Celermajer DS, Zureik M, Helmer C, Jouven X, Ritchie K, et al. Carotid intima-media thickness in plaque-free site, carotid plaques and coronary heart disease risk prediction in older adults. The Three-City Study. *Atherosclerosis*. 2011;219(2):917-24. Epub 2011/10/19.
30. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Archives of internal medicine*. 2008;168(12):1340-9. Epub 2008/06/25.
31. Dawson DA. Methodological issues in measuring alcohol use. *Alcohol Res Health*. 2003;27(1):18-29.
32. Dufour MC. What is moderate drinking? Defining "drinks" and drinking levels. *Alcohol Res Health*. 1999;23(1):5-14.
33. Nambi V, Chambless L, He M, Folsom AR, Mosley T, Boerwinkle E, et al. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. *European Heart Journal*. 2012;33(2):183-90.
34. In-Beom Jeong J-HB, Ki-Young Kim, Dae-Woo Hyun, Wan-Ho Kim, Ki-Hyun Ryu, Se-Hee Youn, Hee-Jung Lee. The Carotid Intima-Media Thickness as a Screening Test for Coronary Artery Disease. *Korean Circulation J*. 2005(35):460-6.
35. Brock KE, Huang WY, Fraser DR, Ke L, Tseng M, Mason RS, et al. Diabetes prevalence is associated with serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in US middle-aged Caucasian men and women: a cross-sectional analysis within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Br J Nutr*. 2011;106(3):339-44. Epub 2011/07/09.
36. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al. Associations of plasma 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. *American journal of kidney diseases : the official journal of the National Kidney Foundation*.

- 2012;60(4):567-75. Epub 2012/05/25.
37. Lagunova Z, Porojnicu AC, Vieth R, Lindberg FA, Hexeberg S, Moan J. Serum 25-hydroxyvitamin D is a predictor of serum 1,25-dihydroxyvitamin D in overweight and obese patients. *J Nutr*. 2011;141(1):112-7. Epub 2010/11/19.
  38. Jumi Heo YP, Hyoung Moo Park. Dietary Intake of Nutrients and Food in Postmenopausal Korean Women. *J Korean Soc Menopause*. 2011;17(1):12-20.
  39. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2009;20(11):1807-20. Epub 2009/06/23.
  40. Carnevale V, Modoni S, Pileri M, Di Giorgio A, Chiodini I, Minisola S, et al. Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2001;12(12):1026-30. Epub 2002/02/16.
  41. Khan AH, Iqbal R, Naureen G, Dar FJ, Ahmed FN. Prevalence of vitamin D deficiency and its correlates: results of a community-based study conducted in Karachi, Pakistan. *Archives of osteoporosis*. 2012. Epub 2012/11/16.
  42. Nguyen HT, von Schoultz B, Nguyen TV, Dzung DN, Duc PT, Thuy VT, et al. Vitamin D deficiency in northern Vietnam: prevalence, risk factors and associations with bone mineral density. *Bone*. 2012;51(6):1029-34. Epub 2012/08/11.
  43. Choi HS, Oh HJ, Choi H, Choi WH, Kim JG, Kim KM, et al. Vitamin D insufficiency in Korea--a greater threat to younger generation: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008. *J Clin Endocrinol Metab*. 2011;96(3):643-51. Epub 2010/12/31.
  44. Correale J, Ysraelit MC, Gaitan MI. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. *J Immunol*. 2010;185(8):4948-58. Epub 2010/09/22.
  45. Gray TK, McAdoo T, Hatley L, Lester GE, Thierry M. Fluctuation of serum concentration of 1,25-dihydroxyvitamin D3 during the menstrual cycle. *American journal of obstetrics and gynecology*. 1982;144(8):880-4. Epub 1982/12/15.
  46. Aarskog D, Aksnes L, Markestad T, Rodland O. Effect of estrogen on vitamin D metabolism in tall girls. *J Clin Endocrinol Metab*. 1983;57(6):1155-8. Epub 1983/12/01.
  47. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and

early postpartum: Implications for autoimmune disease activity during these times. *J Clin Endocr Metab.* 2001;86(10):4933-8.

48. Schnatz PF, Marakovits KA, O'Sullivan DM, Ethun K, Clarkson TB, Appt SE. Response to an adequate dietary intake of vitamin D3 modulates the effect of estrogen therapy on bone density. *J Womens Health (Larchmt).* 2012;21(8):858-64. Epub 2012/06/14.

49. Spence JD. Carotid plaque measurement is superior to IMT Invited editorial comment on: carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis-Yoichi Inaba, M.D., Jennifer A. Chen M.D., Steven R. Bergmann M.D., Ph.D. *Atherosclerosis.* 2012;220(1):34-5. Epub 2011/08/02.

50. Pollex RL, Hegele R. Genetic determinants of carotid ultrasound traits. *Current atherosclerosis reports.* 2006;8(3):206-15. Epub 2006/04/28.